Lars Masanneck, Leoni Rolfes, Liesa Regner-Nelke, Alice Willison, Saskia Räuber, Falk Steffen, Stefan Bittner, Frauke Zipp, Philipp Albrecht, Tobias Ruck, Hans-Peter Hartung, Sven G. Meuth, Marc Pawlitzki
- Background:
The current range of disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has placed more importance on the accurate monitoring of disease progression for timely and appropriate treatment decisions. With a rising number of measurements for disease progression, it is currently unclear how well these measurements or combinations of them can monitor more mildly affected RRMS patients.
Objectives:
To investigate several composite measures for monitoring disease activity and their potential relation to the biomarker neurofilament light chain (NfL) in a clearly defined early RRMS patient cohort with a milder disease course.
Methods:
From a total of 301 RRMS patients, a subset of 46 patients being treated with a continuous first-line therapy was analyzed for loss of no evidence of disease activity (lo-NEDA-3) status, relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA), up to seven years after treatment initialization.
Kaplan-Meier estimates wereBackground:
The current range of disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has placed more importance on the accurate monitoring of disease progression for timely and appropriate treatment decisions. With a rising number of measurements for disease progression, it is currently unclear how well these measurements or combinations of them can monitor more mildly affected RRMS patients.
Objectives:
To investigate several composite measures for monitoring disease activity and their potential relation to the biomarker neurofilament light chain (NfL) in a clearly defined early RRMS patient cohort with a milder disease course.
Methods:
From a total of 301 RRMS patients, a subset of 46 patients being treated with a continuous first-line therapy was analyzed for loss of no evidence of disease activity (lo-NEDA-3) status, relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA), up to seven years after treatment initialization.
Kaplan-Meier estimates were used for time-to-event analysis. Additionally, a Cox regression model was used to analyze the effect of NIL levels on outcome measures in this cohort.
Results:
In this mildly affected cohort, both lo-NEDA-3 and PIRA frequently occurred over a median observational period of 67.2 months and were observed in 39 (84.8%) and 23 (50.0%) patients, respectively.
Additionally, 12 out of 26 PIRA manifestations (46.2%) were observed without a corresponding lo-NEDA-3 status. Jointly, either PIRA or lo-NEDA-3 showed disease activity in all patients followed-up for at least the median duration (67.2 months). NfL values demonstrated an association with the occurrence of relapses and RAW.
Conclusion:
The complementary use of different disease progression measures helps mirror ongoing disease activity in mildly affected early RRMS patients being treated with continuous first-line therapy.…
MetadatenAuthor details: | Lars MasanneckORCiDGND, Leoni Rolfes, Liesa Regner-Nelke, Alice Willison, Saskia Räuber, Falk Steffen, Stefan BittnerORCiD, Frauke Zipp, Philipp Albrecht, Tobias RuckORCiD, Hans-Peter Hartung, Sven G. Meuth, Marc Pawlitzki |
---|
DOI: | https://doi.org/10.1016/j.msard.2022.103927 |
---|
ISSN: | 2211-0348 |
---|
ISSN: | 2211-0356 |
---|
Pubmed ID: | https://pubmed.ncbi.nlm.nih.gov/35700670 |
---|
Title of parent work (English): | Multiple Sclerosis and Related Disorders |
---|
Publisher: | Elsevier |
---|
Place of publishing: | Amsterdam |
---|
Publication type: | Article |
---|
Language: | English |
---|
Date of first publication: | 2022/05/28 |
---|
Publication year: | 2022 |
---|
Release date: | 2024/09/13 |
---|
Tag: | NEDA; PIRA; RAW; biomarker; disease activity measurements; early MS; neurofilament light chain; relapsing-remitting multiple sclerosis |
---|
Volume: | 63 |
---|
Article number: | 103927 |
---|
Number of pages: | 12 |
---|
Organizational units: | Digital Engineering Fakultät / Hasso-Plattner-Institut für Digital Engineering GmbH |
---|
DDC classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Peer review: | Referiert |
---|
Publishing method: | Open Access / Hybrid Open-Access |
---|
License (German): | CC-BY - Namensnennung 4.0 International |
---|